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Patients with diabetes mellitus (DM) have a markedly higher overall mortality from 
coronary heart disease (CHD), as well as many other causes of death, like cancer. 
Recent studies indicate that mortality gap between people with diabetes and general 
population may have narrowed 
What	this	study	adds? 
 
The difference between DM and reference populations in stroke mortality vanished 
with a later entrance to the follow-up period. There were a few differences between 
DM and no DM groups regarding how baseline medications were associated with 
mortality. The gap between the mortality of diabetic patients compared to non-diabetic 
subjects diminished markedly during the 21-year period. This was driven primarily by 









Patients with diabetes mellitus (DM) have a markedly higher overall mortality from coronary heart 
disease (CHD), as well as many other causes of death, like cancer. Since diabetes is a multisystem 
disease, this fact together with the increased lifespan among individuals with diabetes may also lead 
to the emergence of other diabetes-related complications and ultimately to diversification of the 




The study population of this observational historic cohort study consisted of DM subjects, who had 
purchased for at least one insulin prescription and/or one oral antidiabetic between January 1, 1997 
and December 31, 2010 (N=199,354), and a reference population matched by age, sex, and hospital 
district (N=199,354). Follow-up was continued until December 31, 2017. All-cause and cause-
specific mortality (cancer, CHD, and stroke) were analysed with Poisson and Cox’s regression. 




The mortality rates were significantly elevated among the patients with DM. However, the relative 
risk of all-cause mortality between the DM and reference populations tended to converge during the 
follow-up. The lowering trend was most apparent in CHD mortality. The difference between DM 
and reference populations in stroke mortality vanished with a later entrance to the follow-up period. 
There were a few differences between DM and no DM groups regarding how baseline medications 




The gap between the mortality of diabetic patients compared to non-diabetic subjects diminished 
markedly during the 21-year period. This was driven primarily by the reduced CHD mortality.   
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Patients with diabetes mellitus (DM) have markedly higher overall mortality from cardiovascular 
diseases (CVD) especially, but also many other causes of death, such as cancer, renal and liver 
diseases, infections and intentional self-harm as well as traumatic causes, which contribute to 
excess premature mortality [1–9]. In high-income countries, a decline in CVD mortality has been 
observed, but the simultaneous increase in the prevalence of diabetes, especially type 2 diabetes, 
implies that more patients are at an increased risk of CVDs. According to estimates of Global 
Burden of Disease study years of life lost (YLL) have increased globally for DM between 2006 and 
2016, with a percentage change of 25.3 [10]. On the other hand, the age-standardised rate (per 
100,000) decreased by 2.1 during the same period. 
It is conceivable that the increasing incidence of diabetes and the declining mortality indicate that 
the total life years spent with diabetes has increased. As diabetes is a multisystem disease, this 
increased life span may also lead to the emergence of other diabetes-related complications and 
ultimately to diversification of the causes of death. The diagnosis of type 2 diabetes markedly 
affects YLLs. The Emerging Risk Factors Collaboration (EFRC) reported that an average 60-year-
old man with diabetes but without a history of vascular disease is about 6 years younger at the time 
of death than a counterpart without diabetes [7]. According to the EFRC report, 40% of YLLs due 
to diabetes can be attributed to nonvascular conditions. Vigorous treatment of cardiovascular risk 
factors and improved diabetes detection and treatment may cause time-related changes in mortality 
patterns and thus affect the relative causes of death and YLLs. For example, recent register data 
from Sweden showed that if major risk factors, like smoking, HbA1c, blood pressure, albuminuria 
and LDL cholesterol were under control, the risk of cardiac events approximated to a counterpart 
without known diabetes [11]. We analysed all-cause mortality as well as cause-specific mortality of 
the main causes of death in a large national cohort including all the insulin-treated patients and a 
random sample of half of those treated with oral antidiabetic drugs as well as a matched control 
group from the general population. Our data do not include information on risk factors such as 
blood pressure or lipid levels or smoking. Instead, we have purchases of prescribed drugs as proxies 
for unobserved risk factors. We analysed association between baseline drug usage and mortality, 
and compared predictors for DM and no DM populations. The aim of this study is to investigate 
trends in mortality of diabetic population compared to its reference population, and to describe 
factors connected to the mortality. 
 
Methods 
The study population was constructed based on the CARING Project [12] in Finland. The study 
population consisted of two groups. Diabetes mellitus (DM) patients included individuals who had 
purchased and received reimbursement for at least one insulin prescription having the Anatomical 
Therapeutic Chemical (ATC) code of A10A [13] and/or one oral antidiabetic (OAD) prescription 
(ATC code A10B) between January 1, 1997 and December 31, 2010. The reference group was 
individually matched to the DM group by sex, age (±1 year), region (hospital district) and start of 
the follow-up date. In the original population, all the insulin users in Finland in this period were 
included as well as a 50% random sample of the OAD users. The size of the population was 
398,708 individuals, comprising 199,354 DM reference pairs.   
The study plan was approved by the Faculty of Medicine, University of Helsinki’s ethical 
committee on January 17, 2012 (Ref 02/2012). We obtained the prescription data from the Social 
Insurance Institution (SII) (permission Kela 16/522/2012). Cancer data was obtained from the 
Finnish Cancer Registry [14], and it included the diagnosis (ICD-O-3 code)[15] and date of 
diagnosis (THL/264/5.05.00/2012). 
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Follow-up started on the date of the first diabetes medication prescription, and ended on December 
31, 2017 or on the date of death, whichever occurred first. The year 1996 was the initial wash-in 
period, meaning that it was guaranteed that no individual in the study population had a prescription 
within the 12 months before the start of the follow-up. 
We obtained the information of death (the date and cause of death) and socio-economic group from 
Statistics Finland (permission TK-53-214-12)[16]. We used death from any cause, coronary heart 
disease (CHD) (ICD-10 I20-I25), stroke (I60-I69), and cancer (C00-C97) as the end-point events. 
Loss of follow-up was assumed to be negligibly low. 
We had information on the following drug prescriptions (ATC code, date, amount of purchased 
medications in  defined daily dose DDD) [13] from the whole study period (1996–2017): A10 
(drugs used in diabetes), G03 (sex hormones and modulators of the genital system), H01 (pituitary 
and hypothalamic hormones and analogues), H02A (corticosteroids for systemic use, plain), H03A 
(thyroid preparations), H03B (antithyroid preparations), L01 (antineoplastic agents), L02 (endocrine 
therapy), L03 (immunostimulants), L04 (immunosuppressants), M04 (anti-gout preparations), M05 
(drugs for treatment of bone diseases), N03 (anti-epileptics), N04 (anti-Parkinson’s drugs), N05 
(psycholeptics), and N06 (psychoanaleptics). 
We categorised subjects into two groups by diabetes medication at the start of the follow-up: people 
with any antidiabetic medication (insulin or oral antidiabetics) and people without any DM 
medication. Diagnosis of cancer before the baseline (yes/no) was determined using the data from 
the Finnish Cancer Registry. Data on the following special reimbursement rights were obtained 
from the SII: severe mental disorder, chronic heart failure, hypertension, CVD, arrhythmia, 
ulcerative colitis. 
We analysed the cohort data using conditional Poisson regression [17] models with cumulated 
follow-up time taken into account separately for each end-point. The following variables were used 
in models: diabetes group, cancer before baseline, severe mental disorder, chronic heart failure, 
hypertension, CVD, arrhythmia, ulcerative colitis, and socio-economic group. In conditional 
Poisson regression models, matching was taken into account using an “eliminate” method, thus sex, 
age, calendar year at the start of follow-up, and hospital district were not included in model, 
because matching was based on these variables. Results from the Poisson regression models are 
reported using mortality rate ratios (MRR).  
We analysed the competing risks for four causes of death (CHD, stroke, cancer, other causes) using 
competing risks regression [18,19].  
Years of life lost (YLL) were calculated as the difference of the areas under the survival curves (10 
year periods conditional to surviving to age 60 years, separately for men and women) comparing 
people with DM to the reference population. Predicted survival curves were based on Cox’s 
proportional hazards models with the diabetes group, age, sex, year of start of follow-up, cancer 
before baseline, severe mental disorder, chronic heart failure, hypertension, CVD, arrhythmia, 
ulcerative colitis, and socio-economic group. Hospital district was used as the strata. 
We studied the association between medication in the year before the start of follow-up (SOF) and 
mortality using LASSO (Least Absolute Shrinkage and Selection Operator) Poisson models with 
cumulated follow-up time as the offset [20]. The number of different medications in the whole 
study population (ATC codes A08, A10, C01, C02, C03, C04, C05, C07, C08, C09, C10, G03, 
H01, H02, H03, L01, L02, L03, L04, M04, M05, N03, N04, N05, N06, N07 were available) used in 
the year before SOF was 404. We included only substances with 500 or more users in both DM and 
no DM populations (N=97) in LASSO. In addition, the following variables were always included in 
LASSO: age, sex, SOF year, and socio-economic group. Diabetes medications (ATC codes A10) 
were not included because our aim was to compare DM and no DM populations. Separate analyses 
were carried out for DM and no DM groups, and for men and women. The aim was to compare 
LASSO predictors for DM and no DM groups. The parameter l of LASSO was searched for by 
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cross-validation and one standard error from the minimum l value was used [21]. Results are 
reported as MRRs, with a value of one meaning that the variable is not in the LASSO model. 
All results are reported with 95% confidence intervals. Analyses were carried out using R data-
analysis language [22] and packages Epi [23] and timereg [19]. 
 
Results 
The study population consisted of 398,708 individuals (199,354 pairs), 208,538 men and 190,170 
women (Table 1). The mean follow-up time was 11.3 years. Altogether, we observed 117,604 
deaths, of which 30,268 were from CHD, 26,986 from cancer, and 10,129 from stroke (Table 2). 
The mortality rates were significantly elevated among the patients with diabetes (Appendix Figure 1 
and Tables 2–4). Of note, stroke mortality was significantly higher in women than men, in 
unadjusted results.  
Cumulative mortality curves (Appendix Figure 2) showed that proportions of the four causes of 
death (other, cancer, stroke, and CHD) remained about same during the follow-up in the no DM 
group, but in the DM group the proportion of deaths due to cancer decreased  about after five years 
from the start of follow-up and then plateaued. 
In all-cause mortality, the adjusted MRR between DM and reference populations was 1.68 (95% 
confidence interval of 1.66–1.71), 1.80 (1.75–1.86) for cancer, 2.12 (2.07–2.18) for CHD, and 1.41 
(1.35–1.47) for stroke mortality (Table 4). Socio-economic group had a relatively large effect on the 
risk of both all-cause mortality and cause-specific mortalities. 
There was a considerable lowering of CHD and stroke mortality in the DM group compared to the 
reference population, and also a slight decrease in all-cause mortality in later start of follow-ups 
(SOF) (Appendix Figures 3, Figure 1). In cancer mortality, we detected no declining trend in 
relative risk for later SOF years.    
Estimated YLLs due to DM within 15 years of the start of follow-up diminished considerably 
according to the calendar year of initiation of the follow-up (time when DM was detected). For a 
man in his 60s without cancer YLL in 15 years was 0.51 years if DM was detected in 1998 and 0.44 
years if DM was detected in 2002. For a woman with the same characteristics, YLLs were 0.26 and 
0.22 years, respectively (Appendix Table 1).  
 
LASSO models 
There were 30 substances that were included in both male and female LASSO models (Appendix 
Figures 4 and 5). For men, there were 37 drugs that were in the LASSO of either DM, no DM or 
both, and for women there were 35 drugs. The following seven drugs were only in the male models: 
glyceryl trinitrate (C01DA02), hydrochlorothiazide and potassium-sparing agents (C03EA01), 
fluocortolone (C05AA08), propranolol (C07AA05), verapamil (C08DA01), captopril (C09AA01), 
and candesartan (C09CA06). The following five drugs were only in the female models: enalapril 
(C09AA02), estradiol (G03CA03), norethisterone and estrogen (G03FA01), risedronic acid 
(M05BA07), and perphenazine (N05AB03).  
Usage of levodopa and decarboxylase inhibitor (N04BA02) predicted the highest risk of all-cause 
mortality, with the risk for the DM group being considerably lower than that for the no DM group. 
A similar association was also observed for quetiapine (N05AH04) and risperidone (N05AX08). On 
the other hand, usage of prednisone (H02AB07) predicted a higher risk of all-cause mortality for the 
DM group. Simvastatin predicted a lower risk for all, in both men and women. Usage of estradiol 
(G03CA03) predicted low risk in women similarly in both groups. Interestingly, rosuvastatin 




The main finding of our study is that the difference in total mortality between the diabetic subjects 
and their reference population in Finland converged markedly during the 21-year period from 1997 
to 2017. Thus, the main driver for the decrease in the risk rate ratios and YLLs is due to a decrease 
in cardiovascular mortality and its risk factors. On the other hand, a marked increase in the 
incidence of diabetes occurred in Finland, similar to elsewhere, thus the burden of diabetes 
increased in quantitative aspects [24,25]. However, in Sweden, in contrast to the results reported 
from many other countries, the incidence decreased modestly between 2005 and 2013, while the 
prevalence of pharmacologically treated diabetes increased moderately  [26].  Further, during the 
follow-up period, a nationwide programme was on-going whose purpose was to increase the 
awareness of diabetes, the early identification of persons at high risk and the prevention and early 
treatment of type 2 diabetes [9]. Thus, the clinical diagnosis of diabetes may have occurred at an 
earlier phase than during the previous periods and therefore early treatment may have improved the 
prognosis of diabetes. To support this concept the report from recent population-based health survey 
indicates that the increasing incidence of diabetes has levelled off and further, the proportion of 
unidentified diabetes in the populations is relatively low (3.1 % in men, 1.4 in women)[24]. 
 
 
The reduction caused by cardiovascular disease mortality in this nationwide cohort is mainly 
consistent with previous reports of decreased cardiovascular mortality and risk of myocardial 
infarction. These findings are also relatively well in line with geographically and culturally closely 
related studies from Sweden.  In Laxå area excess mortality in diabetic patients was very low, but 
they experienced less mortality reduction than reference population (Jansson et al 2010)[27]. More 
recent studies from Sweden show decreasing excess total and cardiovascular mortality in patients 
with type 2 diabetes, but  noteworthy is high excess risk in younger (< 55 years) type 2 diabetic 
patients [28,29]. This reduction in total mortality is dominated by the reduction of cardiovascular 
mortality and is likely due to the efficient treatment of cardiovascular risk factors, especially 
dyslipidaemia with statins and reductions in smoking. During era of our study, the concept of type 2 
diabetes being seen as a cardiovascular risk factor emerged in clinical knowledge, and widespread 
campaigns to identify and treat cardiovascular risk factors in diabetes were promoted, as well as 
national current care guidelines emphasizing comprehensive risk assessment and active treatment. 
Regarding stroke mortality, the excess relative risk in diabetic patients disappeared with increasing 
calendar year. The reason for this finding remains obscure. In a recent Swedish study, systolic blood 
pressure and HbA1c as well as duration of diabetes were important risk factors for stroke [11]. 
Since we in this study did not have access to those risk factors, the role of these in this respect 
remains speculative.  
 
From non-vascular causes of death, the cancer mortality was about 50% higher in diabetic patients 
than in non-diabetic subjects, accounting for one-fourth of the total mortality (Appendix Figure 2).   
Further, we observed that the proportion of cancer deaths decreased during the follow-up within the 
DM group (Appendix Figure 2). The reason for this may be that  the onset of diabetes (requiring 
physician visits) leads to the increased detection of cancers, of which some are fatal.   
Other non-vascular, non-cancer causes of death comprise a very heterogenous group. From the 
same cohort, we recently published the analysis of non-natural causes of death where the suicidal, 
traumatic and alcohol-related deaths were also higher in the diabetic than non-diabetic subjects [4].     
It is also possible that some diabetic subjects were treated only with lifestyle interventions, not with 
medication. However, since lifestyle interventions are difficult to implement and may unnecessarily 
delay the start of drug treatment, the Finnish Current Care guideline (original version published in 
2007 and thereafter updated several times) recommended that drug treatment with metformin 
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should be initiated, if not contraindicated, concomitantly with lifestyle interventions. These 
guidelines have been shown to have good penetrance in primary care [30], and therefore it is likely 
that those clinically diagnosed with diabetes were included in the study. 
Analyses of baseline medications revealed some difference in risk between DM and no DM groups. 
We found that DM users of quetiapine, risperidone and digoxin had a lower relative risk compared 
to users with no DM that is in line with observation that in primary care, structured diabetes care 
was highly effective among diabetic patients with co-occurring psychiatric illness [31]. Both 
quetiapine and risperidone are widely used antipsychotics, and the increased all-cause relative 
mortality among the no DM group using these antipsychotics may indicate that those patients with 
co-morbid DM and psychotic disorder were better taken care of compared to the reference 
population with psychotic disorder. 
Concerning sex differences, propranol was associated with a higher risk in men in the DM group, 
whereas valproic acid and mirtazapine were associated with a higher risk in women in the DM 
group. Interestingly, estrogen users in the DM group were at a lower risk. However, valproic acid is 
widely prescribed not only for the treatment of epilepsy but also for bipolar disorder, and 
mirtazapine not only for depressive disorder but also for insomnia (although as off-label). 
These associations with medications may be due to the effect of the drug substance, or due to the 
indication of the drug. In the latter case, a drug is a proxy for the condition it was prescribed for. Or, 
there may be a selective prescription practice for the DM group. However, observations of risk 
differences are worth further study in order to detect reasons for them. 
This register-based cohort study has other limitations as well. We did not have access to risk factors 
like body mass index, LDL cholesterol, blood pressure levels and smoking, exercise habit nor to 
diabetic complications. Differences in these may have partly explained differences in mortality 
between no-DM and DM groups. Another crucial limitation is that we used antidiabetic medication 
use as indicator for DM. Inclusion of diabetic individuals into no-DM group may attenuate the 
difference between groups, because individuals with diabetes without treatment are in higher risks. 
 
Better care for diabetic patients may be cause for decreasing gap in mortality between diabetic 
population and general population. Well organized and intensive case management provides 
individuals with diabetes good access to preventive health care, which leads to lower mortality in 
due to main preventable causes of death like cardiovascular diseases and stroke. Results of Swedish 
study [11], where patients with diabetes and well-managed risk factors were compared with a 
reference group of people free from diabetes, but with risk factors as they appear in the general 
population are similar to this study. Results of Swedish study may also be partly due to same cause, 
risk factors of reference population were not measured, and in reality, risk factors of reference 
population may have been under estimated. 
 
In conclusion, our study shows that a difference in cardiovascular mortality between the diabetic 
subjects and their reference population in Finland has converged markedly in the 21-year period of 
1997 to 2010. However, during the same period, the difference in cancer mortality between patients 
with DM and their reference population has increased. During the study period, YLLs due to 
diabetes has decreased in both men and women.  
 
 
To conclude, the pattern of excess mortality in diabetic subjects is changing and this has preventive 
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Table 1 Basic characteristics of study population at start of follow-up, frequencies (%).   








Female 95085 (47.7) 95085 (47.7) 
    
Age 0–30 14841 (7.4) 14841 (7.4) 
 
30–60 84326 (42.3) 84326 (42.3) 
 




Start of follow-up 1997–2001 48850 (24.5) 48850 (24.5) 
 
2002–2006 63617 (31.9) 63617 (31.9) 
 
2007–2011 86887 (43.6) 86887 (43.6) 
Cancer 
 
5307 (2.7) 7703 (3.9) 
Severe mental disorder 
 
4713 (2.4) 8721 (4.4) 
Chronic heart failure 
 
4308 (2.2) 8809 (4.4) 
Hypertension 
 
32514 (16.3) 59564 (29.9) 
Cardiovascular disease 
 
14270 (7.2) 21211 (10.6) 
Arrythmia 
 
3376 (1.7) 5003 (2.5) 
Ulcerative colitis 
 
1085 (0.5) 1277 (0.6) 
Socio-economic group Upper-level 
employees 




4302 (2.2) 3467 (1.7) 
 




27747 (13.9) 24070 (12.1) 
 
Manual workers 29579 (14.8) 29051 (14.6) 
 
Students 3588 (1.8) 3611 (1.8) 
 
Pensioners 88304 (44.3) 96200 (48.3) 
 
Others 13578 (6.8) 15411 (7.7) 
 
Unknown 4973 (2.5) 5847 (2.9) 
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Table 2. Number of deaths and all-cause mortality rates (per 1000 person-years) with 95% confidence intervals for baseline characteristics. 
 
No DM DM 
  P-years Events Rate (95% CI) P-
years 
Events Rate (95% CI) 
Sex Male 1219 25925 21.26 (21.01-21.52) 1119 36943 33.01 (32.67-33.35)  
Female 1113 23702 21.29 (21.02-21.56) 1045 31034 29.70 (29.37-30.03) 
Age 0–30 198 98 0.49 (0.40-0.60) 197 301 1.53 (1.36-1.71) 
 
30–60 1088 6987 6.42 (6.27-6.57) 1024 15331 14.97 (14.74-15.21) 
 
over 60 1046 42542 40.67 (40.28-41.06) 943 52345 55.49 (55.02-55.97) 
Start of follow-up 1997–2001 771 18770 24.35 (24.00-24.70) 687 25730 37.47 (37.01-37.93) 
 
2002–2006 806 16988 21.08 (20.77-21.40) 747 23783 31.83 (31.42-32.23) 
 
2007–2011 756 13869 18.34 (18.04-18.65) 730 18464 25.29 (24.93-25.66) 
Cancer no 2287 46809 20.47 (20.29-20.66) 2112 62788 29.73 (29.50-29.96) 
 
yes 46 2818 61.25 (59.01-63.55) 52 5189 99.74 (97.05-102.49) 
Severe mental disorder no 2285 47629 20.85 (20.66-21.03) 2074 64571 31.13 (30.90-31.38) 
 
yes 48 1998 41.76 (39.95-43.63) 90 3406 37.79 (36.54-39.08) 
Chronic heart failure no 2299 46216 20.11 (19.92-20.29) 2098 60832 29.00 (28.77-29.23) 
 
yes 34 3411 100.33 (96.99-103.76) 67 7145 107.38 (104.90-
109.90) 
Hypertension no 1984 36069 18.18 (17.99-18.37) 1539 42421 27.56 (27.30-27.82) 
 
yes 348 13558 38.92 (38.27-39.59) 625 25556 40.91 (40.41-41.42) 
Cardiovascular disease no 2194 41685 19.00 (18.82-19.18) 1970 55588 28.22 (27.98-28.45) 
 
yes 139 7942 57.26 (56.01-58.54) 194 12389 63.87 (62.75-65.01) 
Arrythmia no 2301 47694 20.73 (20.54-20.91) 2122 64687 30.49 (30.25-30.72) 
 
yes 32 1933 61.26 (58.56-64.06) 42 3290 77.80 (75.16-80.50) 
Ulcerative colitis no 2321 49406 21.29 (21.10-21.48) 2151 67590 31.43 (31.19-31.67) 
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yes 12 221 18.45 (16.10-21.05) 13 387 28.90 (26.09-31.93) 
Socio-economic group Upper-level employees 235 856 3.64 (3.40-3.89) 167 1428 8.54 (8.10-9.00) 
 
Self-employed persons 59 381 6.49 (5.86-7.18) 46 641 13.97 (12.91-15.10) 
 
Farmer 112 625 5.57 (5.14-6.03) 99 1328 13.40 (12.69-14.14) 
 
Lower-level employees 351 1317 3.75 (3.55-3.96) 294 2381 8.09 (7.77-8.43) 
 
Manual workers 380 2383 6.28 (6.03-6.53) 352 4365 12.39 (12.03-12.77) 
 
Students 47 118 2.52 (2.09-3.02) 46 247 5.41 (4.76-6.13) 
 
Pensioners 914 41141 45.03 (44.59-45.46) 912 52177 57.20 (56.71-57.70) 
 
Others 176 2023 11.51 (11.02-12.03) 186 3702 19.89 (19.25-20.54) 
 
Unknown 59 783 13.17 (12.26-14.13) 62 1708 27.72 (26.42-29.06) 
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Table 3. Cause-specific death and mortality rates per 1000 person-years.   
Cancer (C00-C97) CHD (I20-I25) Stroke (I60-I69) 
  No DM DM 
 
No DM DM 
 
No DM DM 
 
  N Rate N Rate N Rate N Rate N Rate N Rate 
Sex Male 6595 5.41 9015 8.06 6263 5.14 10853 9.70 1987 1.63 2521 2.25  
Female 4650 4.18 6726 6.44 5006 4.50 8146 7.80 2542 2.28 3079 2.95 
Age 0–30 15 0.08 29 0.15 <5 0.00 8 0.04 <5 0.01 <5 0.02  
30–60 2278 2.09 4047 3.95 1123 1.03 3346 3.27 380 0.35 677 0.66  
over 60 8952 8.56 11665 12.37 10146 9.70 15645 16.59 4147 3.96 4920 5.22 
Start of follow-up 1997–2001 3926 5.09 5041 7.34 4576 5.94 8174 11.90 1801 2.34 2403 3.50  
2002–2006 3835 4.76 5583 7.47 3890 4.83 6459 8.64 1515 1.88 1944 2.60  
2007–2011 3484 4.61 5117 7.01 2803 3.71 4366 5.98 1213 1.60 1253 1.72 
Cancer no 9806 4.29 12574 5.95 10853 4.75 18213 8.62 4372 1.91 5389 2.55  
yes 1439 31.28 3167 60.87 416 9.04 786 15.11 157 3.41 211 4.06 
Severe mental disorder no 10941 4.79 15083 7.27 10878 4.76 18146 8.75 4349 1.90 5362 2.59  
yes 304 6.35 658 7.30 391 8.17 853 9.47 180 3.76 238 2.64 
Chronic heart failure no 10832 4.71 14794 7.05 10020 4.36 16139 7.69 4211 1.83 5017 2.39  
yes 413 12.15 947 14.23 1249 36.74 2860 42.98 318 9.35 583 8.76 
Hypertension no 8697 4.38 10219 6.64 7629 3.84 11137 7.23 3063 1.54 3197 2.08  
yes 2548 7.32 5522 8.84 3640 10.45 7862 12.59 1466 4.21 2403 3.85 
Cardiovascular disease no 9969 4.54 13640 6.92 8047 3.67 13288 6.74 3822 1.74 4600 2.33  
yes 1276 9.20 2101 10.83 3222 23.23 5711 29.44 707 5.10 1000 5.16 
Arrythmia no 10939 4.75 15222 7.17 10689 4.65 17917 8.44 4324 1.88 5291 2.49  
yes 306 9.70 519 12.27 580 18.38 1082 25.59 205 6.50 309 7.31 
Ulcerative colitis no 11184 4.82 15635 7.27 11210 4.83 18890 8.78 4509 1.94 5576 2.59 
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yes 61 5.09 106 7.92 59 4.93 109 8.14 20 1.67 24 1.79 
Socio-economic group Upper-level 
employees 385 1.64 499 2.98 126 0.54 290 1.73 40 0.17 67 0.40  
Self-employed 
persons 144 2.45 176 3.84 66 1.12 162 3.53 27 0.46 48 1.05  
Farmer 245 2.18 425 4.29 110 0.98 313 3.16 41 0.37 78 0.79  
Lower-level 
employees 599 1.71 919 3.12 157 0.45 416 1.41 74 0.21 91 0.31  
Manual workers 889 2.34 1344 3.82 442 1.16 1022 2.90 102 0.27 206 0.58  
Students 30 0.64 61 1.34 22 0.47 44 0.96 6 0.13 12 0.26  
Pensioners 8158 8.93 10901 11.95 9853 10.78 15563 17.06 4063 4.45 4821 5.29  
Others 597 3.40 888 4.77 368 2.09 807 4.34 114 0.65 172 0.92  
Unknown 198 3.33 528 8.57 125 2.10 382 6.20 62 1.04 105 1.70 
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Table 4 Mortality rate ratios (95% confidence intervals) based on conditional Poisson model for sex, age, and hospital district matched cohort 
design.    
All-cause Cancer CHD Stroke 
  Univariate 
DM vs no DM  1.88 (1.85-1.90) 2.15 (2.09-2.21) 2.47 (2.40-2.53) 1.52 (1.46-1.59) 
  Multivariate 
DM vs no DM 
 
1.68 (1.66-1.71) 1.80 (1.75-1.86) 2.12 (2.07-2.18) 1.41 (1.35-1.47) 
Cancer vs no 
 
3.33 (3.19-3.48) 30.84 (28.32-33.58) 0.90 (0.82-0.99) 0.83 (0.71-0.98) 
Severe mental disorder vs no 
 
1.99 (1.89-2.10) 1.29 (1.15-1.45) 1.78 (1.60-1.98) 1.75 (1.47-2.07) 
Chronic heart failure vs no 
 
1.49 (1.44-1.55) 1.17 (1.06-1.29) 1.89 (1.77-2.03) 1.15 (1.02-1.30) 
Hypertension vs no 
 
1.15 (1.12-1.17) 0.98 (0.94-1.02) 1.36 (1.31-1.41) 1.41 (1.32-1.51) 
Cardiovascular disease vs no 
 
1.18 (1.15-1.21) 0.84 (0.79-0.90) 2.58 (2.46-2.71) 1.07 (0.98-1.16) 
Arrythmia vs no 
 
1.15 (1.09-1.21) 0.87 (0.78-0.98) 1.11 (1.01-1.22) 1.39 (1.19-1.63) 
Ulcerative colitis vs no 
 
1.00 (0.88-1.14) 1.03 (0.79-1.34) 1.13 (0.86-1.48) 1.03 (0.64-1.66) 
Socio-economic group vs upper -
level employees 
Self-employed persons 1.46 (1.31-1.63) 1.07 (0.88-1.30) 1.24 (0.98-1.57) 2.04 (1.34-3.10) 
 
Farmer 1.48 (1.36-1.62) 1.18 (1.01-1.39) 1.65 (1.35-2.01) 1.97 (1.36-2.86) 
 
Lower-level employees 1.25 (1.16-1.35) 1.25 (1.10-1.42) 1.09 (0.91-1.30) 1.40 (1.00-1.95) 
 
Manual workers 1.86 (1.74-1.99) 1.67 (1.48-1.89) 1.93 (1.65-2.25) 1.70 (1.25-2.30) 
 
Students 2.39 (1.99-2.87) 1.86 (1.30-2.64) 3.79 (2.38-6.04) 3.30 (1.43-7.57) 
 
Pensioners 3.92 (3.67-4.18) 2.07 (1.84-2.33) 3.36 (2.90-3.91) 4.28 (3.22-5.69) 
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Others 3.75 (3.49-4.04) 2.09 (1.83-2.39) 3.41 (2.88-4.02) 3.11 (2.27-4.26) 
 




Figure 1.  Mortality rate ratios with 95% confidence intervals for comparing DM to no DM. Results from 
Poisson regression models adjusted for sex, age, start of follow-up year, hospital district, socio-





Appendix Figure 1.  Survival after start of follow-up in diabetes groups. 
 
 
Appendix Figure 2.  Cumulative mortality for causes of death, calculation started 0.5 years after the 
start of follow-up. Top actual values, bottom proportions of causes of death. Causes of death in 
shades of grey: other (light grey), stroke (grey), CHD (dark grey), cancer (black). 
 
 
Appendix Figure 3. Unadjusted mortality rate (1000 person-years) with 95% confidence intervals 





Appendix Figure 4.  LASSO model for males. Mortality rate ratios for no DM (grey) and DM (black) 
populations. Models include age, sex, SOF year, and socio-economic group. A value of one (on 






Appendix Figure 5.  LASSO model for females. Mortality rate ratios for no DM (grey) and DM (black) 
populations. Models include age, sex, SOF year, and socio-economic group. A value of one (on 





Appendix Table 1Years of life lost in 15 years follow-up due to DM. 
Start of follow-up period Male Female 
1997-1999 0.51 0.26 
2000-2001 0.47 0.24 
2002-2003 0.44 0.22 
 
